Gastroenterology
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
Hyo Young Lee, Dae Won Jun, Hyun Jung Kim, Hyunwoo Oh, Waqar Khalid Saeed, Hyeongsik Ahn, Ramsey C. Cheung, Mindie H. Nguyen
Korean J Intern Med. 2019;34(2):296-304. Published online March 20, 2018
Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD..
|